Pexidartinib
Cat.No:IP2270 Solarbio
CAS:1029044-16-3
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Angiogenesis >
PexidartinibCAS:1029044-16-3
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
CAS | 1029044-16-3 |
Name | Pexidartinib |
Molecular Formula | C20H15ClF3N5 |
Molecular Weight | 417.81 |
Solubility | Soluble in DMSO(Need ultrasonic) |
Purity | ≥98% |
Appearance | Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD28900745 |
SMILES | C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F |
InChIKey | JGWRKYUXBBNENE-UHFFFAOYSA-N |
InChI | InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29) |
PubChem CID | 25151352 |
Target Point | c-Kit;c-FMS (CSF-1R) |
Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
Background | Pexidartinib is an effective and selective ATP-competitive CSF1R and c-Kit inhibitor. Pexidartinib can induce apoptosis and has anti-tumor activity. |
Biological Activity | Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity[1]. |
IC50 | IC50: 10nM(c-Kit);20nM(cFMS);160nM(FLT3);350nM(KDR);860nM(LCK);880nM(FLT1);890nM(NTRK3)[1] |
In Vitro | Pexidartinib(PLX-3397)is a potent,selective and ATP-competitive CSF1R(cFMS)and c-Kit inhibitor,shows 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases,such as FLT3,KDR(VEGFR2),LCK,FLT1(VEGFR1)and NTRK3(TRKC),with IC50s of 160,350,860,880,and 890 nM,respectively[1]. |
In Vivo | Pexidartinib(PLX3397; 0.25,1 mg/kg,twice daily for 8 days)inhibits the proliferation of microglia and BrdU-positive cells in neonatal mice[2].Pexidartinib(1 mg/kg,twice daily for 8 day)shows no obvious effect on the cleaved caspase-3-positive cells in mice[2]. |
Data Literature Source | [1]. DeNardo DG,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1(1):54-67. [2]. Kuse Y,et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018. |
Unit | Bottle |
Specification | 5mg 10mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.